COVID-19 pandemic: Impact on gestational diabetes mellitus prevalence.
Covid-19 pandemic
Gestational Diabetes Mellitus
Lockdown
Journal
Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
13
06
2021
revised:
29
10
2021
accepted:
17
11
2021
pubmed:
23
11
2021
medline:
9
2
2022
entrez:
22
11
2021
Statut:
ppublish
Résumé
Although an increased risk of gestational diabetes mellitus (GDM) has been noted in women exposed to stressful conditions and traumatic events, limited information is available about such risk in the context of the COVID-19 pandemic. The study was designed as a non-concurrent case-control study on the prevalence of GDM, defined according to IADPSG 2010, in women giving birth during the COVID-19 pandemic in the hot spot of Northeast Italy from March 9th to May 18th, 2020, with an antecedent puerperae-matched group whose women had given birth in 2019. Analysis revealed that during the COVID-19 pandemic in 2020, GDM prevalence was significantly higher than in 2019 (GDM, 48/533, 9 vs 86/637, 13.5%, p = 0.01), as illustrated by a higher GDM prevalence in 5/6 months of the final semester of 2020. In addition, logistic regression analysisconfirmed a statistically significant temporal relationship between experiencing the lockdown during the first trimester of gestation and later GDM incidence (t = 2.765, P = 0.012), with an 34% increase in mean number of GDM diagnoses per month (antilog of the parameter = 1.34). The COVID-19 pandemic negatively impacted GDM prevalence in 2020 compared to 2019, especially for pregnant women in the 1st trimester of gestation.
Identifiants
pubmed: 34808282
pii: S0168-8227(21)00509-X
doi: 10.1016/j.diabres.2021.109149
pmc: PMC8665826
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109149Informations de copyright
Copyright © 2021. Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Trends Immunol. 2004 Jan;25(1):4-7
pubmed: 14698276
Metabolism. 2015 Nov;64(11):1485-9
pubmed: 26362726
Fetal Diagn Ther. 2019;45(2):76-84
pubmed: 29898442
Diabetes Care. 2010 Mar;33(3):676-82
pubmed: 20190296
Am J Obstet Gynecol. 1991 Dec;165(6 Pt 1):1667-72
pubmed: 1750458
Curr Diab Rep. 2017 Feb;17(2):12
pubmed: 28229385
Curr Opin Psychiatry. 2012 Mar;25(2):141-8
pubmed: 22262028
Annu Rev Public Health. 2015 Mar 18;36:441-62
pubmed: 25581145
Eur J Endocrinol. 2016 Feb;174(2):R43-51
pubmed: 26431552
Metabolism. 2016 Mar;65(3):131-7
pubmed: 26892524
Diabetes. 2003 Jul;52(7):1799-805
pubmed: 12829649
Emerg Infect Dis. 2004 Jul;10(7):1206-12
pubmed: 15324539
Int J Gynaecol Obstet. 2020 Aug;150(2):184-188
pubmed: 32474910
Can J Psychiatry. 2009 May;54(5):302-11
pubmed: 19497162
Acta Biomed. 2020 Jul 20;91(9-S):19-21
pubmed: 32701912
Int J Epidemiol. 2013 Aug;42(4):1187-95
pubmed: 23760528
Metab Syndr Relat Disord. 2010 Dec;8(6):483-7
pubmed: 21034178
Nat Rev Endocrinol. 2012 Nov;8(11):639-49
pubmed: 22751341
J Clin Med. 2020 Feb 22;9(2):
pubmed: 32098435
Annu Rev Psychol. 2019 Jan 4;70:577-597
pubmed: 29949726
Diabetologia. 2016 Jul;59(7):1396-1399
pubmed: 27174368
Stress Health. 2020 Apr;36(2):160-165
pubmed: 31714017
Int J Mol Sci. 2018 Oct 26;19(11):
pubmed: 30373146
Arch Endocrinol Metab. 2019 Mar-Apr;63(2):121-127
pubmed: 31038593
Nature. 2020 Aug;584(7821):425-429
pubmed: 32604404
Endocrinology. 1992 Mar;130(3):1459-66
pubmed: 1537300